HALIFAX,
April 11, 2013 /CNW/ - MedMira Inc.,
(MedMira) (TSXV: MIR), a developer of rapid diagnostic technology
and solutions, is attending the US Food and Drug Administration
Public Workshop on advances in multiplex testing taking place this
week in Bethesda, MD.
Participation in this workshop is particularly timely, as MedMira
advances a new multiplex rapid test for the simultaneous detection
of HIV and Hepatitis B and C towards clinical trials and the FDA
approval process under a United States Army Medical Research
Acquisition Activity (USAMRAA) contract. It is anticipated
that various branches of the US military would use the test in
emergency medical situations and for screening transfusion
transmitted diseases.
The purpose of the FDA Public Workshop, planned
in partnership with the AABB, Advanced Medical Technology
Association (AdvaMed), America's Blood Centers, Department of
Health and Human Services Offices of the Assistant Secretary of
Health and the National Heart, Lung, and Blood Institute (NIH), is
to discuss research and development of multiplex assays and the use
of these tests in blood donor screening and blood cell antigen
typing.
Since being awarded the USAMRAA contract to
develop and commercialize the Multiplo HBc/HIV/HCV Rapid Antibody
Test in 2012, the Company has seen a growing interest in its
multiplex rapid tests and technology platform from various
organizations and individual researchers in the US, and around the
world. The Company was also recently invited to submit its
multiplex test for HIV and Syphilis to the World Health
Organization (WHO) Prequalification of Diagnostics program.
"We receive several inquiries a week about our
Multiplo product line from clinics, laboratories, life sciences
researchers, and organ/tissue banks," said Neeraj Vats, Director of
Technology and Business Affairs, MedMira Inc. "There are
significant advantages in multiplex testing that these healthcare
providers and researchers are looking for, including costs and time
saving, the use of a single sample on one device, and the ability
to screen for diseases that share similar infection paths such as
blood and impact standard treatment regimens."
Vats continued, "Our multiplex rapid tests and
technology platform, which surpass the capabilities of other rapid
diagnostics on the market today, open up a fresh landscape for
healthcare providers to radically increase their efficiency in
diagnosing and treating patients."
About MedMira
MedMira is a leading developer and manufacturer
of flow-through rapid diagnostics. The company's tests provide
hospitals, labs, clinics and individuals with reliable, rapid
diagnosis for diseases such as HIV and hepatitis C in just three
minutes. The company's tests are sold under the Reveal®, Multiplo™
and Miriad brands in global markets. MedMira's rapid flow-through
HIV test is the only one in the world to achieve regulatory
approvals in Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For
more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. This press release
does not constitute any endorsement from the U.S. Army or the
USAMRAA.
SOURCE MEDMIRA INC.